HCPCS Codes Similar to C9297

HCPCS Codes Similar to “C9297” Code.
Injection, omacetaxine mepesuccinate, 0.01 mg

J9262 Injection, omacetaxine mepesuccinate, 0.01 mg Code added date: 20140101 Code effective date: 20140101 TXT \| PDF \| XML \| JSON	C9045 Injection, moxetumomab pasudotox-tdfk, 0.01 mg Code added date: 20190401 Code effective date: 20191001 TXT \| PDF \| XML \| JSON
C9450 Injection, fluocinolone acetonide intravitreal implant, 0.01 mg Code added date: 20150401 Code effective date: 20160101 TXT \| PDF \| XML \| JSON	J0461 Injection, atropine sulfate, 0.01 mg Code added date: 20100101 Code effective date: 20100101 TXT \| PDF \| XML \| JSON
J0462 Injection, atropine sulfate, not therapeutically equivalent to j0461, 0.01 mg Code added date: 20251001 Code effective date: 20251001 TXT \| PDF \| XML \| JSON	J0775 Injection, collagenase, clostridium histolyticum, 0.01 mg Code added date: 20110101 Code effective date: 20110101 TXT \| PDF \| XML \| JSON
J1612 Injection, glucagon (gvoke), 0.01 mg Code added date: 20251001 Code effective date: 20251001 TXT \| PDF \| XML \| JSON	J2312 Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg Code added date: 20250701 Code effective date: 20250701 TXT \| PDF \| XML \| JSON
J2313 Injection, naloxone hydrochloride (zimhi), 0.01 mg Code added date: 20250701 Code effective date: 20250701 TXT \| PDF \| XML \| JSON	J7311 Injection, fluocinolone acetonide, intravitreal implant (retisert), 0.01 mg Code added date: 20070101 Code effective date: 20191001 TXT \| PDF \| XML \| JSON
J7313 Injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg Code added date: 20160101 Code effective date: 20191001 TXT \| PDF \| XML \| JSON	J7314 Injection, fluocinolone acetonide, intravitreal implant (yutiq), 0.01 mg Code added date: 20191001 Code effective date: 20191001 TXT \| PDF \| XML \| JSON
J9313 Injection, moxetumomab pasudotox-tdfk, 0.01 mg Code added date: 20191001 Code effective date: 20191001 TXT \| PDF \| XML \| JSON	Q0220 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg Code added date: 20211208 Code effective date: 20241213 TXT \| PDF \| XML \| JSON